Angiotensin-converting enzyme inhibitors

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Pharmacology

Background:

• Angiotensin-converting enzyme (ACE) inhibitors are crucial in managing hypertension.
• ACE inhibitors target the renin-angiotensin system, influencing blood pressure and fluid balance.
• Understanding ACE inhibitor mechanisms is key for optimizing patient outcomes.

Purpose of the Study:

• To summarize key indications and considerations for ACE inhibitor therapy.
• To highlight the biochemical action of ACE-1 (kininase II) on angiotensin and bradykinin.
• To review factors affecting ACE inhibitor efficacy and safety.

Main Methods:

• Review of established clinical guidelines and pharmacological principles.
• Analysis of the biochemical role of ACE in the renin-angiotensin system.
• Examination of clinical data regarding ACE inhibitor effects and adverse events.

Main Results:

• ACE inhibitors are indicated for hypertension, high cardiovascular risk, post-myocardial infarction, dilated cardiomyopathy, and chronic kidney disease.
• ACE-1 inactivates bradykinin and converts angiotensin I to angiotensin II; bypass pathways lack clinical significance in humans.
• Dietary sodium impacts efficacy; salt restriction or diuretics enhance effects. Renal protective benefits are indicated by increased creatinine.
• Contraindicated in pregnancy due to fetal toxicity. Side effects include cough, angioedema, hyperkalemia, and hypotension.

Conclusions:

• ACE inhibitors offer broad therapeutic benefits beyond hypertension, particularly in cardiovascular and renal protection.
• Careful patient selection and monitoring are essential to maximize benefits and minimize risks like hyperkalemia and hypotension.
• Understanding individual responses and drug interactions, such as with sodium intake, is vital for effective ACE inhibitor therapy.